PHBI.US Pharmagreen Biotech Inc
- Market cap
- USD 231M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Mar 2026.
Is PHBI.US undervalued?
Graham numberThe Graham number of Pharmagreen Biotech Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pharmagreen Biotech Inc fundamental analysis
No fundamental analysis for Pharmagreen Biotech Inc yet.
Pharmagreen Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pharmagreen Biotech Inc
Pharmagreen Biotech Inc. operates as a nutraceutical company, engages in the formulating products from blends of therapeutic plants and fungi in North America. The company's primary product is MaxGenomic supplement, a proprietary blend and formulated medicinal mushrooms and medical plants to support the human mind and body. It also provides consulting services for plant genetic selection, tissue culture technologies for starter plantlets production, SOPs for cultivation and …
Full company profilePharmagreen Biotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pharmagreen Biotech Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2009 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 3.41K | 2.39K | 8.67M |
| Gross Profit | - | 0.00 | 0.00 | - | -435K | -435K | - | -6.45K | 1.74K | -400.00 | - |
| Operating Income | -69.7K | -19.0K | -670K | -652K | -271K | -515K | -1.07M | -474K | -248K | -290K | -2.38M |
| EBITDA | -69.7K | -19.0K | -400K | -658K | -56.8K | -277K | 242K | 26.0K | 182.00 | -290K | -2.38M |
| Net Income | -69.7K | -19.0K | -1.07M | -890K | -3.32M | -5.54M | -875K | -569K | -1.00M | 406K | -2.33M |
| EPS | -520 | -1.84 | -87 | -24 | -81 | -38 | -4.33 | -2.44 | -3.05 | 0.62 | -7.03 |
| Balance Sheet | |||||||||||
| Total Assets | - | 3.93K | 449K | 630K | 266K | 373K | 209K | 122K | 97.7K | 7.54K | 822K |
| Total Liabilities | 11.4K | 91.2K | 1.84M | 1.46M | 3.20M | 2.07M | 2.03M | 2.30M | 3.23M | 2.69M | 10.2M |
| Shareholders' Equity | -11.4K | -87.3K | -1.39M | -833K | -2.89M | -1.65M | -1.78M | -2.13M | -3.09M | -2.63M | -9.42M |
| Cash & Short-term Investments | - | 21.25 | 152K | 62.7K | 12.2K | 25.3K | 8.02K | 1.25K | 276.00 | 721.00 | 235K |
| Total Debt | 2.78K | 15.4K | 693.00 | 76.7K | 715K | 270K | 339K | 373K | 356K | 356K | 266K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -61.1K | -21.1K | -786K | -318K | -608K | -206K | -427K | -73.8K | -28.1K | -23.3K | - |
| Capital Expenditure | 0.00 | 3.91K | 251K | 196K | 0.00 | 0.00 | 0.00 | 2.00 | 4.00 | 4.00 | - |
| Free Cash Flow | -61.1K | -25.0K | -1.04M | -514K | -608K | -206K | -427K | -73.8K | -28.1K | -23.3K | - |
| Ratios | |||||||||||
| ROA | - | -483.0% | -239.0% | -141.3% | -1,248.7% | -1,484.7% | -418.7% | -468.1% | -1,027.8% | 5,387.3% | -283.7% |
| Net Profit Margin | - | - | - | - | - | - | - | -18,979.3% | -29,442.8% | 17,016.9% | -26.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Pharmagreen Biotech Inc dividends
Pharmagreen Biotech Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:2000 on Aug 12, 2026.
Who owns Pharmagreen Biotech Inc
- Insiders 12.77%
- Institutions 0.00%
- Public & others 87.23%
- Shares outstanding 691M
- Free float 625M
Pharmagreen Biotech Inc company profile
- Company name
- Pharmagreen Biotech Inc
- Ticker
- PHBI.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- September
- Address
- 2987 Blackbear Court, Coquitlam, BC, Canada, V3E 3A2
- Phone
- 702 803 9404
- Website
- pharmagreen.ca
About Pharmagreen Biotech Inc
Pharmagreen Biotech Inc. operates as a nutraceutical company, engages in the formulating products from blends of therapeutic plants and fungi in North America. The company's primary product is MaxGenomic supplement, a proprietary blend and formulated medicinal mushrooms and medical plants to support the human mind and body. It also provides consulting services for plant genetic selection, tissue culture technologies for starter plantlets production, SOPs for cultivation and live storage of any plant species services. It sells its products through online stores, such as Amazon and Shopify. Pharmagreen Biotech Inc. is headquartered in Coquitlam, Canada.
Pharmagreen Biotech Inc management
2- Mr. Peter Wojcik B.A.President, CEO, Secretary, Treasurer & Director · born 1972
- Mr. Terry Kwan B.Com., C.A., CPACFO & Principal Accounting Officer · born 1948